Health coverage company Centene (NYSE: CNC) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.1% year on year to $49.94 billion. The company expects the full year’s revenue to be around $189.5 billion, close to analysts’ estimates. Its non-GAAP profit of $3.37 per share was 57.9% above analysts’ consensus estimates.

Is now the time to buy CNC? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Centene’s first quarter results were met with a significant positive market reaction, reflecting stronger-than-expected operating performance across key business lines. Management attributed this to ongoing margin improvement in Medicaid, effective cost controls, and stabilized trends in high-cost areas such as behavioral health and specialty drugs. CEO Sarah London highlighted that a lighter flu season and favorable weather events contributed positively, while initiatives to modernize processes and combat fraud and waste continued to support financial results. The company also pointed to stronger-than-anticipated performance in its Medicare and Part D businesses, bolstered by better member retention and a favorable shift in risk scores.

Looking ahead, Centene’s raised guidance is underpinned by management’s confidence in further margin recovery, particularly in its Medicaid and Marketplace segments. The company is adopting a prudent stance, emphasizing that risk adjustment mechanisms in the health insurance marketplace are expected to offset higher member acuity in key product tiers. CFO Drew Asher noted that the June Wakely data will be critical in refining risk transfer assumptions, stating, “We have not accounted for the full potential risk adjustment offset suggested by the data we currently have.” Management remains focused on operational discipline, enhanced data analytics, and constructive engagement with state partners as they navigate evolving regulatory and market dynamics.

Key Insights from Management’s Remarks

Centene’s management credited the quarter’s outperformance to successful trend management in Medicaid, targeted improvements in Medicare and PDP, and strong operational execution in Marketplace despite shifting member mix.

• Medicaid margin initiatives: Management’s multi-pronged efforts—including utilization management, expanded clinical programs, and stricter fraud controls—drove margin improvement, with London highlighting “continued progress in the HBR with Q1 at 93.1%, an improvement of 50 basis points.”
• Behavioral health and specialty drugs: While these remain key cost drivers, management noted signs of stabilization, especially in behavioral health utilization, as states and providers adopt more evidence-based guidelines and benefit designs.
• Medicare segment execution: Outperformance in both Medicare Advantage and Part D Prescription Drug Plans was attributed to better-than-expected member retention and disciplined pricing. London emphasized progress on value-based care models and a strategic shift toward higher-quality provider networks.
• Marketplace risk pool dynamics: The expiration of enhanced subsidies led to a healthier-than-expected overall market and a shift of members from Silver to Bronze plans. Management credited early data sharing among industry peers and the new Wakely report for increased risk visibility, supporting prudent assumptions for risk adjustment offsets.
• Leadership structure changes: The appointment of Dan Finke as Group President for Medicaid and Commercial businesses and Michael Carson for Medicare PDP and Specialty businesses was cited as a move to strengthen execution and drive sustainable growth across the portfolio.

Drivers of Future Performance

Centene’s forward guidance is shaped by ongoing margin recovery efforts, evolving risk adjustment dynamics in Marketplace, and continued operational improvements in Medicaid and Medicare.

• Marketplace risk adjustment offset: Management is awaiting June Wakely data to confirm the magnitude of risk adjustment receivables tied to higher-acuity Silver tier membership. While only a portion is reflected in current guidance, a full offset could boost Marketplace margins above the conservative 3% assumption.
• Medicaid and state partnerships: The company’s outlook assumes steady rate adjustments and further adoption of cost-saving initiatives, with management highlighting constructive conversations with states regarding acuity shifts and work requirements that could impact future rates and membership mix.
• Operational discipline and analytics: Centene continues to deploy advanced analytics and selective AI-enabled tools across forecasting, medical economics, and payment integrity, aiming to enhance visibility into medical trends, reduce fraud, and ensure tighter cost management to support margin targets.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will closely monitor (1) the June Wakely risk adjustment data and its implications for Marketplace margins, (2) the effectiveness of Medicaid cost containment and fraud prevention initiatives as states roll out new work requirements and policy changes, and (3) continued progress in Medicare Advantage and PDP, especially in managing specialty drug costs. Updates on leadership execution and AI-driven analytics will also be key signposts for sustained margin recovery.

Centene currently trades at $49.59, up from $43.60 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.